S. Daniel Haldar, MD, explains the future directions for evaluating NeoAg-VAX in colorectal and pancreatic cancer.
S. Daniel Haldar, MD
Advertisement
S. Daniel Haldar, MD, is an assistant professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, and an adjunct assistant professor in the Department of Oncology at Johns Hopkins University School of Medicine
Articles by S. Daniel Haldar, MD
S. Daniel Haldar, MD, discusses outcomes for NeoAg-Vax with or without pembrolizumab in MSS metastatic colorectal cancer.
Advertisement
Latest Updated Articles
Dr Haldar on Outcomes for NeoAg-VAX With or Without Pembrolizumab in MSS mCRCPublished: April 28th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5